87 patients aged 40-69 years in the period of pre- and postmenopause were examined. In the analysis of age-related dynamics of bone mineral density (BMD) It was found that densitometry indicators corresponding to osteoporosis directly correlate with age and duration of the postmenopausal period. It is advisable in women of this age group with a decrease in bone mineral density, the combined appointment of menopausal hormone therapy (MGT) and non-hormonal therapy affecting bone metabolism (calcitonin). For the purpose of MGT in premenopausal women, the use of femostone 2/10 is effective, in postmenopausal women - femostone 1/10 and femostone 1/5, which does not cause withdrawal bleeding. If there are contraindications to menopausal hormone therapy, the prevention and treatment of osteoporosis should be guided by the appointment of nonhormonal drugs, in particular, calcitonin.
Effects of Adding Intravenous Pamidronate to Ongoing Menopausal Hormone Therapy in Postmenopausal Korean Women with Low Bone Mineral Density
